drugset / Trial / NCT03335098
Study of VTD in Waldenstrom's Macroglobulinemia
Phase 2
Unknown
15 enrolled
Seoul National University Hospital
Seoul National University Bundang Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.
Timeline
- Start
- 2016-11-21
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Subject | Thalidomide | Other / unclassified | 50 mg | Oral |